Organogenesis Holdings Inc. (ORGO): who owns it and who trades it
As of Nov 16, 2026, ORGO insiders reported 4 open-market sales worth $2.6M and 2 purchases worth $40.1K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Glenn H Nussdorf (Director), with $2.6M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Organogenesis
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ORGO
134 funds and institutions reported ORGO shares worth $168M at the end of Q2 2026, about 54% of the company. The largest holder is Morgan Stanley with 9.1%.
Funds and institutions (13F) 54%Everyone else 46%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Morgan Stanley | 11.72M | 9.11% | $28.5M | +1% |
| Soleus Capital Management, L.P. | 10.14M | 7.88% | $24.6M | +1% |
| BlackRock, Inc. | 7.25M | 5.63% | $17.6M | +48% |
| Assenagon Asset Management S.A. | 3.94M | 3.06% | $9.6M | +100% |
| Dimensional Fund Advisors LP | 3.05M | 2.37% | $7.4M | +6% |
| AQR Capital Management LLC | 3.01M | 2.34% | $7.3M | +242% |
| Vanguard Capital Management LLC | 2.91M | 2.26% | $7.1M | +0% |
| D. E. Shaw & Co., Inc. | 2.89M | 2.24% | $7M | +26% |
| Geode Capital Management, LLC | 1.94M | 1.50% | $4.7M | +8% |
| Deutsche Bank Ag\ | 1.71M | 1.33% | $4.1M | No change |
| Vanguard Portfolio Management LLC | 1.61M | 1.25% | $3.9M | +11% |
| Acadian Asset Management LLC | 1.55M | 1.20% | $3.7M | -2% |
| State Street Corp | 1.52M | 1.18% | $3.7M | -0% |
| Renaissance Technologies LLC | 1.02M | 0.79% | $2.5M | -5% |
| Charles Schwab Investment Management Inc | 905,024 | 0.70% | $2.2M | +3% |
| Sixth Street Partners Management Company, L.P. | 905,024 | 0.70% | $2.2M | – |
| Goldman Sachs Group Inc | 887,399 | 0.69% | $2.2M | +71% |
| Citadel Advisors LLC | 867,929 | 0.67% | $2.1M | +59% |
| Flax Pond Capital, LLC | 842,682 | 0.65% | $2M | +101% |
| SG Americas Securities, LLC | 772,737 | 0.60% | $1.9M | -2% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, ORGO insiders reported $40.1K of open-market purchases and $2.6M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Mar 9, 2026 | Arthur S Leibowitz | Director | Purchase | 5,000 | $2.68 | $13.4K | Form 4 |
| Mar 9, 2026 | Michael Joseph Driscoll | Director | Purchase | 10,000 | $2.67 | $26.7K | Form 4 |
| Dec 16, 2025 | Glenn H Nussdorf | Director | Sale | 200,000 | $5.14 | $1M | Form 4 |
| Nov 26, 2025 | Glenn H Nussdorf | Director | Sale | 187,957 | $5.29 | $994K | Form 4 |
| Nov 25, 2025 | Glenn H Nussdorf | Director | Sale | 12,043 | $5.30 | $63.8K | Form 4 |
| Nov 24, 2025 | Glenn H Nussdorf | Director | Sale | 100,000 | $5.34 | $534K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Glenn H Nussdorf | Director, 10% owner | – | $2.6M | Dec 16, 2025 |
| Michael Joseph Driscoll | Director | $26.7K | – | Mar 9, 2026 |
| Arthur S Leibowitz | Director | $13.4K | – | Mar 9, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ORGO short interest
High short interest. 12.0% of ORGO shares are sold short: about 1 share in 8. Over the last 12 reports the number of shares short went down 4%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 15.61M ORGO shares were sold short, 12.0% of the shares outstanding, up 0.2% from the report before. At the average daily volume of 1.11M shares, buying them all back would take about 14.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 15.61M | 12.03% | +0% | 1.11M | 14.0 |
| Oct 15, 2026 | 15.59M | 12.12% | +4% | 736,923 | 21.2 |
| Sep 30, 2026 | 15.00M | 11.66% | +6% | 563,439 | 26.6 |
| Sep 15, 2026 | 14.12M | 10.97% | -1% | 750,274 | 18.8 |
| Aug 31, 2026 | 14.25M | 11.07% | +0% | 594,717 | 24.0 |
| Aug 14, 2026 | 14.23M | 11.06% | +7% | 1.21M | 11.7 |
| Jul 31, 2026 | 13.31M | 10.35% | +1% | 639,597 | 20.8 |
| Jul 15, 2026 | 13.13M | 10.20% | -5% | 779,045 | 16.9 |
| Jun 30, 2026 | 13.80M | 10.73% | +12% | 845,984 | 16.3 |
| Jun 15, 2026 | 12.28M | 9.54% | -8% | 784,438 | 15.7 |
| May 29, 2026 | 13.30M | 10.33% | -18% | 1.15M | 11.6 |
| May 15, 2026 | 16.23M | 12.61% | +2% | 1.92M | 8.5 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Organogenesis company events
Organogenesis filed 8 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Aug 6, 2026AgreementOrganogenesis Holdings Inc. entered into an At-the-Market Sales Agreement with BTIG, LLC and Citizens JMP Securities, LLC, each as sales agents thereunder, pursuant to which the Corporation may offer and sell shares of its Class A common stock, $0.0001 par value per share, from time to time through… Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jun 16, 2026LeadershipThe holders of our Series A Convertible Preferred Stock voted by written consent to re-elect Garrett Lustig to our board of directors, to serve until the next Annual Meeting of Stockholders and until his successor is elected and qualified. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Feb 26, 2026ResultsReleased financial results. Filing
- Feb 23, 2026LeadershipThe board of directors of Organogenesis Holdings Inc. appointed Patrick McGuire, 40, to serve as Chief Accounting Officer and principal accounting officer of the Company, effective immediately. Filing
- Dec 29, 2025AgreementOrganogenesis Inc., a wholly owned subsidiary of Organogenesis Holdings Inc., entered into a First Amendment to Lease with 65 Dan Road SPE, LLC, as landlord, relating to the premises located at 65 Dan Road, Canton, Massachusetts, and a separate First Amendment to Lease with Dan Road Associates… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Organogenesis financials
Famous investors that hold ORGO
4 of the 50 well-known investors we track reported holding ORGO in their latest 13F filing. The largest position is Ken Griffin's, worth $1.7M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 1.22M | $1.7M | 0.0% | +41% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 887,300 | $1.2M | 0.0% | -13% |
| Israel Englander · Millennium Management | Q3 2026 | 468,850 | $642K | 0.0% | New |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 63,988 | $87.7K | 0.0% | +164% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Organogenesis Holdings Inc. (ORGO) stock
Who owns the most ORGO stock?
The largest reported owner of Organogenesis Holdings Inc. (ORGO) is Morgan Stanley, with 9.1% of the company. In total, 134 funds and institutions reported holding ORGO at the end of Q2 2026, together about 54% of the shares. See the largest owners.
Are ORGO insiders buying or selling?
In the last 12 months, ORGO insiders reported 2 open-market purchases worth $40.1K and 4 sales worth $2.6M. The latest trade was on Mar 9, 2026. See every trade.
What is the short interest in ORGO?
As of Oct 30, 2026, 15.61M ORGO shares were sold short, 12.0% of the shares outstanding, up 0.2% from the report before. At the average daily volume of 1.11M shares, buying them all back would take about 14.0 trading days (days to cover). See the history.
Which famous investors hold ORGO?
4 of the 50 well-known investors we track reported ORGO in their latest 13F filing, including Ken Griffin, Jim Simons, Israel Englander. The largest position is worth $1.7M. See all holders.
Executive pay
Organogenesis's chief executive was paid a total of $6.8M for the year ended Dec 31, 2025, down 3% from $7M the year before. In the last 12 months, Organogenesis's executives and directors bought $40.1K of stock on the open market and sold $2.6M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.